Mesenchymal Stem Cells Market Size - By Type (Autologous, Allogeneic), Source (Adipose Tissue, Bone Marrow), Indication (Bone & Cartilage Repair, Cardiovascular Diseases), Application & Global Forecast, 2023

Description

List of Tables

Global Mesenchymal Stem Cells Market will witness 12.8% CAGR between 2023 and 2032. The expanding application of mesenchymal stem cells in regenerative medicine, including tissue repair and immunomodulation, is fueling demand. Growing awareness of the potential of these cells in treating various diseases, such as orthopedic and autoimmune disorders, contributes to the mesenchymal stem cells market growth. Additionally, advancements in cell culture techniques and increasing research into stem cell-based therapies further propel market expansion, making it a promising and dynamic industry.

For instance, a recent interim analysis from an open-label trial, revealed at the 2023 MSMilan during the 9th Joint ECTRIMS-ACTRIMS meeting in Milan, Italy, indicated significant positive effects on cognition and objective biomarkers associated with neuroinflammation and neurodegeneration in patients with progressive multiple sclerosis who underwent repeated intrathecal injections of their autologous mesenchymal stem cells.

The overall Mesenchymal Stem Cells Market is classified based on type, application, and region.

The transportation refrigeration equipment segment will undergo significant development from 2023 to 2032. Autologous mesenchymal stem cells are derived from a patient's own tissue, minimizing the risk of rejection or adverse reactions. This approach is particularly valuable in regenerative medicine, where it is used for personalized therapies, such as orthopedic treatments, wound healing, and autoimmune disease management. The demand for autologous mesenchymal stem cells is on the rise, supporting the mesenchymal stem cells market outlook.

The food and beverage distribution segment will register a noteworthy CAGR from 2023 to 2032. These versatile stem cells play a vital role in preclinical research, disease modeling, and drug testing. Their ability to differentiate into various cell types provides a valuable tool for studying disease mechanisms and testing potential therapies. As the pharmaceutical industry advances, the mesenchymal stem cells market demand in drug development and discovery continues to grow.

Europe mesenchymal stem cells market will showcase an appreciable CAGR from 2023 to 2032. This demand is driven by the region's progressive biotechnology and healthcare sectors, which recognize the potential of mesenchymal stem cells in regenerative medicine, drug development, and clinical trials. European countries are increasingly investing in stem cell research and regenerative therapies, making Europe a prominent market for mesenchymal stem cell applications.

Product Code: 6555

Chapter 1 Methodology

1.1 Market definition
1.2 Base estimates & calculations
1.3 Forecast parameters
1.4 COVID-19 impact analysis at global level
1.5 Data validation
1.6 Data Sources
- 1.6.1 Primary
- 1.6.2 Secondary
  - 1.6.2.1 Paid sources
  - 1.6.2.2 Public sources

Chapter 2 Executive Summary

2.1 Mesenchymal stem cells industry 360 degree synopsis, 2018 - 2032
- 2.1.1 Business trends
- 2.1.2 Regional trends
- 2.1.3 Products & services trends
- 2.1.4 Type trends
- 2.1.5 Source trends
- 2.1.6 Indication trends
- 2.1.7 Application trends

Chapter 3 Mesenchymal Stem Cells Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Growing awareness regarding regenerative medicine
  - 3.2.1.2 Evolving diverse applications of mesenchymal stem cells
  - 3.2.1.3 Rising prevalence of chronic diseases
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High cost of associated with stem cell treatment
  - 3.2.2.2 Lack of standardized & regulated delivery of stem cell therapy
3.3 Growth potential analysis
- 3.3.1 By products & services
- 3.3.2 By type
- 3.3.3 By source
- 3.3.4 By indication
- 3.3.5 By application
3.4 COVID- 19 impact analysis
3.5 Regulatory landscape
- 3.5.1 U.S.
- 3.5.2 Europe
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Mesenchymal Stem Cells Market, By Products & Services, 2018 - 2032 (USD Million)

5.1 Key trends, by products & services
5.2 Products
- 5.2.1 Kits, media, & reagents
- 5.2.2 Cells & cell lines
- 5.2.3 Other products
5.3 Services

Chapter 6 Mesenchymal Stem Cells Market, By Type, 2018 - 2032 (USD Million)

6.1 Key trends, by type
6.2 Autologous
6.3 Allogeneic

Chapter 7 Mesenchymal Stem Cells Market, By Source, 2018 - 2032 (USD Million)

7.1 Key trends, by source
7.2 Adipose tissue
7.3 Bone marrow
7.4 Cord blood
7.5 Fetal liver
7.6 Fallopian tube
7.7 Lung
7.8 Peripheral blood
7.9 Other sources

Chapter 8 Mesenchymal Stem Cells Market, By Indication, 2018 - 2032 (USD Million)

8.1 Key trends, by indication
8.2 Bone & cartilage repair
8.3 Cardiovascular diseases
8.4 Inflammatory and immunological diseases
8.5 Liver diseases
8.6 Cancer
8.7 Graft versus host disease (GvHD)
8.8 Other indications

Chapter 9 Mesenchymal Stem Cells Market, By Application, 2018 - 2032 (USD Million)

9.1 Key trends, by application
9.2 Disease modeling
9.3 Drug development & discovery
9.4 Stem cell banking
9.5 Tissue engineering
9.6 Toxicology studies
9.7 Other applications

Chapter 10 Mesenchymal Stem Cells Market, By Region, 2018 - 2032 (USD Million)

10.1 Key trends, by region
10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 France
- 10.3.4 Spain
- 10.3.5 Italy
- 10.3.6 Rest of Europe
10.4 Asia Pacific
- 10.4.1 Japan
- 10.4.2 China
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 Rest of Asia Pacific
10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Rest of Latin America
10.6 MEA
- 10.6.1 South Africa
- 10.6.2 Saudi Arabia
- 10.6.3 Rest of MEA

Chapter 11 Company Profiles

11.1 Thermo Fisher Scientific, Inc.
11.2 Cell Applications, Inc.
11.3 Cyagen Biosciences
11.4 Axol Bioscience Ltd.
11.5 Stemedica Cell Technologies, Inc.
11.6 Merck KGaA
11.7 Lonza
11.8 Celprogen Inc.
11.9 PromoCell GmbH
11.10 STEMCELL Technologies